Epinoma, founded in 2020 and headquartered in San Francisco, California, is a diagnostics company specializing in the multi-omics approach to cancer monitoring. The company's core mission is to revolutionize cancer diagnostics by engineering proteins that control the operating system of biology. Epinoma aims to provide more accurate and comprehensive cancer monitoring solutions, leveraging advanced multi-omics techniques to offer cutting-edge diagnostic services.
Notable affiliated individuals and investors include leading experts in biotechnology and prominent venture capital firms. Epinoma has achieved significant milestones in developing its proprietary multi-omics platform, which has shown promising results in early trials. The overall impact of Epinoma's work is poised to enhance the precision and effectiveness of cancer diagnostics, potentially leading to earlier detection and better patient outcomes.
